Search Results
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Marko Stojanovic in
Google Scholar
PubMed
Search for other papers by Zida Wu in
Google Scholar
PubMed
Search for other papers by Craig E Stiles in
Google Scholar
PubMed
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Dragana Miljic in
Google Scholar
PubMed
Insitute of Medical Statistics and Informatics, Belgrade, Serbia
Search for other papers by Ivan Soldatovic in
Google Scholar
PubMed
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Sandra Pekic in
Google Scholar
PubMed
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Mirjana Doknic in
Google Scholar
PubMed
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Milan Petakov in
Google Scholar
PubMed
Search for other papers by Vera Popovic in
Google Scholar
PubMed
Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Background
Aryl hydrocarbon receptor-interacting protein (AIP) is evolutionarily conserved and expressed widely throughout the organism. Loss-of-function AIP mutations predispose to young-onset pituitary adenomas. AIP co-localizes with growth hormone in normal and tumorous somatotroph secretory vesicles. AIP protein is detectable in circulation. We aimed to investigate possible AIP and GH co-secretion, by studying serum AIP and GH levels at baseline and after GH stimulation or suppression, in GH deficiency (GHD) and in acromegaly patients.
Subjects and methods
Insulin tolerance test (ITT) was performed in GHD patients (n = 13) and age-BMI-matched normal GH axis control patients (n = 31). Oral glucose tolerance test (OGTT) was performed in active acromegaly patients (n = 26) and age-BMI-matched normal GH axis control patients (n = 18). In-house immunometric assay was developed for measuring circulating AIP.
Results
Serum AIP levels were in the 0.1 ng/mL range independently of gender, age or BMI. Baseline AIP did not differ between GHD and non-GHD or between acromegaly and patients with no acromegaly. There was no change in peak, trough or area under the curve during OGTT or ITT. Serum AIP did not correlate with GH during ITT or OGTT.
Conclusions
Human circulating serum AIP in vivo was assessed by a novel immunometric assay. AIP levels were independent of age, sex or BMI and unaffected by hypoglycaemia or hyperglycaemia. Despite co-localization in secretory vesicles, AIP and GH did not correlate at baseline or during GH stimulation or suppression tests. A platform of reliable serum AIP measurement is established for further research of its circulatory source, role and impact.
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Mirjana Doknic in
Google Scholar
PubMed
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Marko Stojanovic in
Google Scholar
PubMed
Institute of Medical Statistics and Informatics, Belgrade, Serbia
Search for other papers by Ivan Soldatovic in
Google Scholar
PubMed
Search for other papers by Tatjana Milenkovic in
Google Scholar
PubMed
University Children’s Clinic, Belgrade, Serbia
Search for other papers by Vera Zdravkovic in
Google Scholar
PubMed
University Children’s Clinic, Belgrade, Serbia
Search for other papers by Maja Jesic in
Google Scholar
PubMed
Search for other papers by Sladjana Todorovic in
Google Scholar
PubMed
Mother and Child Health Care Institute of Serbia ‘Dr Vukan Cupic’, Belgrade, Serbia
Search for other papers by Katarina Mitrovic in
Google Scholar
PubMed
Mother and Child Health Care Institute of Serbia ‘Dr Vukan Cupic’, Belgrade, Serbia
Search for other papers by Rade Vukovic in
Google Scholar
PubMed
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Dragana Miljic in
Google Scholar
PubMed
Search for other papers by Dragan Savic in
Google Scholar
PubMed
Search for other papers by Mihajlo Milicevic in
Google Scholar
PubMed
Search for other papers by Aleksandar Stanimirovic in
Google Scholar
PubMed
Clinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia
Search for other papers by Vojislav Bogosavljevic in
Google Scholar
PubMed
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Sandra Pekic in
Google Scholar
PubMed
Institute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Emilija Manojlovic-Gacic in
Google Scholar
PubMed
Search for other papers by Aleksandar Djukic in
Google Scholar
PubMed
Clinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia
Search for other papers by Danica Grujicic in
Google Scholar
PubMed
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for other papers by Milan Petakov in
Google Scholar
PubMed
Objective
To analyze metabolic parameters, body composition (BC), and bone mineral density (BMD) in childhood-onset GH deficiency (COGHD) patients during the transition period (TP).
Design
Single- center, retrospective study was performed on 170 consecutive COGHD patients (age 19.2 ± 2.0 years, range 16–25) transferred after growth completion from two pediatric clinics to the adult endocrine unit. Two separate analyses were performed: (i) cross-sectional analysis of hormonal status, metabolic parameters, BC, and BMD at first evaluation after transfer from pediatrics to the adult department; (ii) longitudinal analysis of BC and BMD dynamics after 3 years of GH replacement therapy (rhGH) in TP.
Results
COGHD was of a congenital cause (CONG) in 50.6% subjects, tumor-related (TUMC) in 23.5%, and idiopathic (IDOP) in 25.9%. TUMC patients had increased insulin and lipids levels (P < 0.01) and lower Z score at L-spine (P < 0.05) compared to CONG and IDOP groups. Patients treated with rhGH in childhood demonstrated lower fat mass and increased BMD compared to the rhGH-untreated group (P < 0.01). Three years of rhGH after growth completion resulted in a significant increase in lean body mass (12.1%) and BMD at L-spine (6.9%), parallel with a decrease in FM (5.2%).
Conclusion
The effect of rhGH in childhood is invaluable for metabolic status, BC, and BMD in transition to adulthood. Tumor-related COGHD subjects are at higher risk for metabolic abnormalities, alteration of body composition, and decreased BMD, compared to those with COGHD of other causes. Continuation of rhGH in transition is important for improving BC and BMD in patients with persistent COGHD.
